California Public Employees Retirement System Sells 35,888 Shares of Elanco Animal Health Incorporated $ELAN

California Public Employees Retirement System cut its stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 4.1% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 830,209 shares of the company’s stock after selling 35,888 shares during the period. California Public Employees Retirement System owned about 0.17% of Elanco Animal Health worth $19,867,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Parallel Advisors LLC lifted its position in shares of Elanco Animal Health by 5.9% during the 4th quarter. Parallel Advisors LLC now owns 7,060 shares of the company’s stock valued at $160,000 after buying an additional 392 shares in the last quarter. Lazard Asset Management LLC increased its holdings in Elanco Animal Health by 0.6% in the 4th quarter. Lazard Asset Management LLC now owns 72,065 shares of the company’s stock worth $1,631,000 after acquiring an additional 425 shares in the last quarter. Northwestern Mutual Investment Management Company LLC increased its holdings in Elanco Animal Health by 0.4% in the 4th quarter. Northwestern Mutual Investment Management Company LLC now owns 111,166 shares of the company’s stock worth $2,516,000 after acquiring an additional 428 shares in the last quarter. Meeder Advisory Services Inc. raised its stake in Elanco Animal Health by 4.8% during the 4th quarter. Meeder Advisory Services Inc. now owns 11,235 shares of the company’s stock worth $254,000 after acquiring an additional 510 shares during the period. Finally, Bessemer Group Inc. raised its stake in Elanco Animal Health by 33.2% during the 1st quarter. Bessemer Group Inc. now owns 2,105 shares of the company’s stock worth $50,000 after acquiring an additional 525 shares during the period. Institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Price Performance

ELAN stock opened at $25.41 on Thursday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.12 and a current ratio of 2.16. The company’s fifty day moving average price is $23.85 and its 200-day moving average price is $23.95. Elanco Animal Health Incorporated has a one year low of $13.39 and a one year high of $27.72. The company has a market capitalization of $12.69 billion, a PE ratio of -50.81, a price-to-earnings-growth ratio of 1.67 and a beta of 1.68.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.40 EPS for the quarter, topping the consensus estimate of $0.34 by $0.06. The business had revenue of $1.37 billion for the quarter, compared to analysts’ expectations of $1.28 billion. Elanco Animal Health had a negative net margin of 4.95% and a positive return on equity of 7.42%. The business’s quarterly revenue was up 14.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.37 EPS. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. On average, equities analysts anticipate that Elanco Animal Health Incorporated will post 1.11 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. Citigroup upped their price target on shares of Elanco Animal Health from $30.00 to $31.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. TD Cowen raised their price objective on shares of Elanco Animal Health from $31.00 to $32.00 and gave the company a “buy” rating in a research report on Thursday, June 18th. Weiss Ratings cut shares of Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a research note on Monday, May 11th. Wall Street Zen downgraded shares of Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a report on Sunday, May 24th. Finally, JPMorgan Chase & Co. increased their price target on Elanco Animal Health from $28.00 to $30.00 and gave the stock an “overweight” rating in a research note on Thursday, May 7th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $28.73.

Insider Transactions at Elanco Animal Health

In other news, insider Rajeev A. Modi bought 4,911 shares of the stock in a transaction dated Friday, May 15th. The stock was purchased at an average price of $20.35 per share, for a total transaction of $99,938.85. Following the acquisition, the insider owned 160,812 shares of the company’s stock, valued at $3,272,524.20. The trade was a 3.15% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Jeffrey N. Simmons bought 4,971 shares of the business’s stock in a transaction dated Friday, May 15th. The shares were acquired at an average cost of $20.09 per share, for a total transaction of $99,867.39. Following the purchase, the chief executive officer owned 171,971 shares of the company’s stock, valued at approximately $3,454,897.39. The trade was a 2.98% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders own 1.14% of the company’s stock.

Elanco Animal Health Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.